Further studies are needed to confirm the findings of this study and to evaluate the generalizability of the results

Oct 13, 2025 by orovajewels.com 8 views

Cha2DS2-VASC-HSF Score Value as a Predictor of Nofropathy Events Induced by Contrast in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention Procedures

Introduction

In the realm of patients' care with acute coronary syndrome, Nofropathy that is induced by contrast (CIN) is one of the serious complications that can occur after the percutaneous coronary intervention (PCI) procedure. Although the PCI was successfully carried out to restore blood flow to the heart, the risk of CIN remains and can lead to an increase in morbidity and mortality in the hospital. Understanding the predictors of CIN is crucial in developing effective preventive strategies to minimize its occurrence. Recent research has shown that Cha2DS2-Vasc-HSF scores can not only predict the severity of coronary artery disease, but also serious cardiovascular events, including CIN, in IMA patients, regardless of atrial fibrillation.

Background

CIN occurs when contrast agents used in the imaging procedure or medical intervention interfere with kidney function. This is a major concern for patients who experience acute myocardial infarction (AMI), because the development of CIN can worsen their health conditions even though the revascularization has been carried out. The use of contrast agents is a common practice in medical imaging, but it can have severe consequences if not managed properly. Recent studies have highlighted the importance of identifying patients at high risk of CIN to develop targeted preventive strategies.

The Role of Cha2DS2-VASC-HSF Scores in Predicting CIN

Cha2DS2-Vasc-HSF scores are a widely used risk assessment tool for predicting the risk of stroke and other cardiovascular events in patients with atrial fibrillation. However, recent research has shown that this score can also be used to predict the risk of CIN in patients with AMI. The Cha2DS2-Vasc-HSF score takes into account various risk factors, including age, sex, hypertension, heart failure, stroke, and vascular disease. By using this score, medical personnel can identify patients at high risk of CIN and take preventive measures to minimize its occurrence.

Methodology

This study aimed to evaluate the predictive value of Cha2DS2-VASC-HSF scores in assessing the risk of CIN in IMA patients undergoing PCI procedures. The study was conducted as an ambisant cohort research involving 53 IMA patients treated in the heart care unit and undergoing PCI procedures. Cha2DS2-VASC-HSF scores were calculated for each patient, and CIN was defined as an increase in creatinine serum levels of more than 0.5 mg/dl or an increase of more than 25% of the baseline value within 24 hours after the procedure.

Results

The results of the study showed that of 53 patients, 14 cases (26.4%) experienced CIN, with a total prevalence of 16.83%. The analysis using the ROC curve showed that more than 5 Cha2DS2-Vasc-HSF score threshold values can be used as predictors for CIN. With a sensitivity of 78.57% and specificity of 66.6% (AUC 0.818, 95% CI 3,018-6.142, P <0.001), this result indicates that this score is quite effective in predicting the risk of CIN. Linear regression analysis provided further insight into the probability of CIN based on the score of Cha2DS2-Vasc-HSF scores.

Conclusion

Based on the results of the study, the Cha2DS2-Vasc-HSF score was proven to have a positive relationship with the CIN event. Therefore, this score can be relied upon as a simple and effective tool to predict the risk of CIN in IMA patients who undergo PCI procedures. By using this score, medical personnel can take more precise preventive steps, so as to increase patient safety during and after coronary intervention procedures. The use of Cha2DS2-VASC-HSF scores provides added value in the management of IMA patients, allowing doctors to be more proactive in preventing serious complications and increasing overall clinical outcomes.

Implications for Clinical Practice

The findings of this study have significant implications for clinical practice. Medical personnel can use the Cha2DS2-VASC-HSF score to identify patients at high risk of CIN and take preventive measures to minimize its occurrence. This can include the use of contrast agents with lower osmolality, the administration of intravenous fluids, and the monitoring of kidney function. By using this score, medical personnel can reduce the risk of CIN and improve patient outcomes.

Limitations of the Study

This study has several limitations. The sample size was relatively small, and the study was conducted in a single center. Further studies are needed to confirm the findings of this study and to evaluate the generalizability of the results. Additionally, the study did not investigate the relationship between the Cha2DS2-VASC-HSF score and other risk factors for CIN.

Future Directions

Future studies should aim to confirm the findings of this study and to evaluate the generalizability of the results. Additionally, studies should investigate the relationship between the Cha2DS2-VASC-HSF score and other risk factors for CIN. The development of a predictive model that incorporates multiple risk factors for CIN could provide a more accurate prediction of the risk of CIN. This could lead to the development of more effective preventive strategies and improved patient outcomes.

Conclusion

In conclusion, the Cha2DS2-VASC-HSF score is a useful tool for predicting the risk of CIN in IMA patients undergoing PCI procedures. By using this score, medical personnel can identify patients at high risk of CIN and take preventive measures to minimize its occurrence. This can lead to improved patient outcomes and reduced morbidity and mortality. Further studies are needed to confirm the findings of this study and to evaluate the generalizability of the results.
Cha2DS2-VASC-HSF Score Value as a Predictor of Nofropathy Events Induced by Contrast in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention Procedures: Q&A

Q: What is the Cha2DS2-VASC-HSF score and how is it used?

A: The Cha2DS2-VASC-HSF score is a widely used risk assessment tool for predicting the risk of stroke and other cardiovascular events in patients with atrial fibrillation. It takes into account various risk factors, including age, sex, hypertension, heart failure, stroke, and vascular disease. In this study, we used the Cha2DS2-VASC-HSF score to predict the risk of CIN in IMA patients undergoing PCI procedures.

Q: What is CIN and why is it a concern?

A: CIN occurs when contrast agents used in the imaging procedure or medical intervention interfere with kidney function. This is a major concern for patients who experience acute myocardial infarction (AMI), because the development of CIN can worsen their health conditions even though the revascularization has been carried out. CIN can lead to an increase in morbidity and mortality in the hospital.

Q: How did you conduct the study?

A: We conducted an ambisant cohort research involving 53 IMA patients treated in the heart care unit and undergoing PCI procedures. Cha2DS2-VASC-HSF scores were calculated for each patient, and CIN was defined as an increase in creatinine serum levels of more than 0.5 mg/dl or an increase of more than 25% of the baseline value within 24 hours after the procedure.

Q: What were the results of the study?

A: The results of the study showed that of 53 patients, 14 cases (26.4%) experienced CIN, with a total prevalence of 16.83%. The analysis using the ROC curve showed that more than 5 Cha2DS2-Vasc-HSF score threshold values can be used as predictors for CIN. With a sensitivity of 78.57% and specificity of 66.6% (AUC 0.818, 95% CI 3,018-6.142, P <0.001), this result indicates that this score is quite effective in predicting the risk of CIN.

Q: What are the implications of the study for clinical practice?

A: The findings of this study have significant implications for clinical practice. Medical personnel can use the Cha2DS2-VASC-HSF score to identify patients at high risk of CIN and take preventive measures to minimize its occurrence. This can include the use of contrast agents with lower osmolality, the administration of intravenous fluids, and the monitoring of kidney function.

Q: What are the limitations of the study?

A: This study has several limitations. The sample size was relatively small, and the study was conducted in a single center. Further studies are needed to confirm the findings of this study and to evaluate the generalizability of the results. Additionally, the study did not investigate the relationship between the Cha2DS2-VASC-HSF score and other risk factors for CIN.

Q: What are the future directions for research?

A: Future studies should aim to confirm the findings of this study and to evaluate the generalizability of the results. Additionally, studies should investigate the relationship between the Cha2DS2-VASC-HSF score and other risk factors for CIN. The development of a predictive model that incorporates multiple risk factors for CIN could provide a more accurate prediction of the risk of CIN. This could lead to the development of more effective preventive strategies and improved patient outcomes.

Q: What are the potential benefits of using the Cha2DS2-VASC-HSF score in clinical practice?

A: The use of the Cha2DS2-VASC-HSF score in clinical practice can lead to improved patient outcomes and reduced morbidity and mortality. By identifying patients at high risk of CIN, medical personnel can take preventive measures to minimize its occurrence. This can include the use of contrast agents with lower osmolality, the administration of intravenous fluids, and the monitoring of kidney function.

Q: What are the potential risks of using the Cha2DS2-VASC-HSF score in clinical practice?

A: The use of the Cha2DS2-VASC-HSF score in clinical practice may lead to overestimation or underestimation of the risk of CIN. This can occur if the score is not used in conjunction with other risk factors or if the score is not updated regularly. Additionally, the use of the Cha2DS2-VASC-HSF score may lead to increased costs and resource utilization.

Q: How can the Cha2DS2-VASC-HSF score be used in conjunction with other risk factors to predict the risk of CIN?

A: The Cha2DS2-VASC-HSF score can be used in conjunction with other risk factors, such as age, sex, hypertension, heart failure, stroke, and vascular disease, to predict the risk of CIN. This can be done by using a predictive model that incorporates multiple risk factors. The development of a predictive model that incorporates multiple risk factors for CIN could provide a more accurate prediction of the risk of CIN.